Business Wire09.09.21
Glytec, the only provider of cloud-based insulin management software across the continuum of care, has appointed Nausheen Moulana as chief technology officer. In this role, Moulana will be responsible for the company’s product and technology vision, strategy and execution.
A highly accomplished technologist in the healthcare, enterprise technology and scientific computing sectors, Moulana brings over 25 years of engineering and operations experience to Glytec. She possesses a deep understanding of developing complex software products and driving process improvement to maximize customer value.
Moulana comes to Glytec from Kyruus, the leader in provider search and scheduling solutions for health systems, where she served as vice president of Engineering & Operations and led multiple teams tasked with delivering multi-channel patient access solutions. She also previously held leadership positions at Attivio (since acquired by ServiceNow) and MathWorks.
“Thousands of hospitals across the country still rely on dated paper protocols to titrate insulin and manage inpatient blood glucose levels. The opportunity for advanced software to simplify these processes and improve patient safety and care is massive,” said Moulana. “I’m honored to join the growing team at Glytec to address this challenge and further revolutionize the way providers care for patients that require insulin in the hospital setting.”
Earlier this year, Glytec closed a $21 million funding round to put significant resources behind accelerating research and product development and scaling into hospitals across the United States. In her new role, Moulana will lead the teams responsible for creating the innovations that continue to strengthen Glytec’s position as the industry leader in insulin management and patient safety. The product development teams will focus on enhancements in provider workflows, EHR integrations, mobile apps at scale and support for other diabetes technology across the continuum of care.
“This has been a record year for Glytec and adding a proven technology leader like Nausheen to the Executive team only builds upon that momentum,” said Ed Furlong, president and CEO, Glytec. “The past year has illuminated the importance of properly managing glycemic issues, especially in the hospital setting. Nausheen will help us meet the growing demand for eGlycemic Management System, enabling Glytec to remain the industry leader for inpatient glycemic management.”
Moulana earned a masters of science degree in electrical engineering from the University of Massachusetts Dartmouth and an MBA from Babson College. Known for her mentorship approach to leadership and advocacy for diversity, equity and inclusion, Moulana is also a startup advisor, speaker and host for several technical and talent events.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its U.S. Food and Drug Administration-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment—including those with and without a diagnosis of diabetes.
A highly accomplished technologist in the healthcare, enterprise technology and scientific computing sectors, Moulana brings over 25 years of engineering and operations experience to Glytec. She possesses a deep understanding of developing complex software products and driving process improvement to maximize customer value.
Moulana comes to Glytec from Kyruus, the leader in provider search and scheduling solutions for health systems, where she served as vice president of Engineering & Operations and led multiple teams tasked with delivering multi-channel patient access solutions. She also previously held leadership positions at Attivio (since acquired by ServiceNow) and MathWorks.
“Thousands of hospitals across the country still rely on dated paper protocols to titrate insulin and manage inpatient blood glucose levels. The opportunity for advanced software to simplify these processes and improve patient safety and care is massive,” said Moulana. “I’m honored to join the growing team at Glytec to address this challenge and further revolutionize the way providers care for patients that require insulin in the hospital setting.”
Earlier this year, Glytec closed a $21 million funding round to put significant resources behind accelerating research and product development and scaling into hospitals across the United States. In her new role, Moulana will lead the teams responsible for creating the innovations that continue to strengthen Glytec’s position as the industry leader in insulin management and patient safety. The product development teams will focus on enhancements in provider workflows, EHR integrations, mobile apps at scale and support for other diabetes technology across the continuum of care.
“This has been a record year for Glytec and adding a proven technology leader like Nausheen to the Executive team only builds upon that momentum,” said Ed Furlong, president and CEO, Glytec. “The past year has illuminated the importance of properly managing glycemic issues, especially in the hospital setting. Nausheen will help us meet the growing demand for eGlycemic Management System, enabling Glytec to remain the industry leader for inpatient glycemic management.”
Moulana earned a masters of science degree in electrical engineering from the University of Massachusetts Dartmouth and an MBA from Babson College. Known for her mentorship approach to leadership and advocacy for diversity, equity and inclusion, Moulana is also a startup advisor, speaker and host for several technical and talent events.
Glytec is the insulin management software company for healthcare providers focused on improving the quality and cost of care. Its U.S. Food and Drug Administration-cleared titration software and proprietary algorithms power the only solution capable of delivering personalized diabetes treatment recommendations across the continuum of care, from hospital to home. With ongoing support from its team of doctors, nurses and technologists headquartered outside of Boston, Glytec improves outcomes and controls costs for the large population of patients requiring insulin treatment—including those with and without a diagnosis of diabetes.
